Verona doses first patient in cystic fibrosis trial of RPL554

This article was originally published here

Verona Pharma has enrolled and dosed the first patient in a Phase 2a clinical study to evaluate RPL554, as a treatment option for cystic fibrosis (CF).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply